stockrowAdaptive Biotechnologies Corporation
ADPT Healthcare Diagnostics & Research
Adaptive Biotechnologies Corporation’s revenue for fiscal 2025 (year ended December 2025) was $277.0 million, up 54.8% from fiscal 2024.
- Revenue
- −10.7%
- EPS
- −66.7%
- Free cash flow
- +201.9%
Quarter to September 2026, against a year earlier
Follow ADPT
Alert me
Adaptive Biotechnologies Corporation (ADPT) EBITDA
Adaptive Biotechnologies Corporation's EBITDA for fiscal 2025 was −$41.8M, compared with −$151.5M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$22.4M. Over the past ten years it has ranged from −$214.0M (fiscal 2023) to −$38.3M (fiscal 2017); the current reading is higher than 89% of that period. Adaptive Biotechnologies Corporation ranks 38th of 49 Diagnostics & Research companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$41.8M | — |
| FY2024 | −$151.5M | — |
| FY2023 | −$214.0M | — |
| FY2022 | −$178.5M | — |
| FY2021 | −$187.8M | — |
| FY2020 | −$143.6M | — |
| FY2019 | −$75.1M | — |
| FY2018 | −$45.0M | — |
| FY2017 | −$38.3M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Jun 2026 | −$12.2M | — |
| Mar 2026 | −$15.5M | — |
| Dec 2025 | −$8.9M | — |
| Sep 2025 | $14.2M | — |
| 28 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| SHC Sotera Health Company compare | $537.0M |
| RDNT RadNet, Inc. compare | $307.7M |
| CDNA CareDx, Inc. compare | $141.4M |
| VCYT Veracyte, Inc. compare | $123.9M |
| BLLN BillionToOne, Inc. compare | $55.6M |
| NEO NeoGenomics, Inc. compare | $17.5M |
| ADPT Adaptive Biotechnologies Corporation | −$22.4M |
| WGS GeneDx Holdings Corp. compare | −$65.5M |
| GRAL GRAIL, Inc. compare | −$400.6M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on ADPT
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement